STRS Ohio’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.62M | Sell |
15,400
-500
| -3% | -$44.3K | 0.01% | 609 |
|
|
2025
Q4 | $1.39M | Sell |
15,900
-1,900
| -11% | -$156K | 0.01% | 623 |
|
|
2025
Q3 | $1.18M | Sell |
17,800
-1,800
| -9% | -$102K | ﹤0.01% | 642 |
|
|
2025
Q2 | $1.08M | Buy |
19,600
+600
| +3% | +$28.8K | ﹤0.01% | 893 |
|
|
2025
Q1 | $919K | Sell |
19,000
-4,500
| -19% | -$189K | ﹤0.01% | 901 |
|
|
2024
Q4 | $907K | Buy |
23,500
+2,000
| +9% | +$87.2K | ﹤0.01% | 888 |
|
|
2024
Q3 | $968K | Sell |
21,500
-3,400
| -14% | -$137K | ﹤0.01% | 923 |
|
|
2024
Q2 | $863K | Buy |
24,900
+23,000
| +1,211% | +$674K | ﹤0.01% | 933 |
|
|
2024
Q1 | $54K | Sell |
1,900
-500
| -21% | -$13.6K | ﹤0.01% | 1761 |
|
|
2023
Q4 | $55K | Sell |
2,400
-9,600
| -80% | -$168K | ﹤0.01% | 1763 |
|
|
2023
Q3 | $200K | Sell |
12,000
-11,700
| -49% | -$227K | ﹤0.01% | 1565 |
|
|
2023
Q2 | $654K | Sell |
23,700
-4,800
| -17% | -$120K | ﹤0.01% | 1121 |
|
|
2023
Q1 | $655K | Buy |
28,500
+13,200
| +86% | +$222K | ﹤0.01% | 1127 |
|
|
2022
Q4 | $166K | Hold |
15,300
| – | – | ﹤0.01% | 1627 |
|
|
2022
Q3 | $128K | Hold |
15,300
| – | – | ﹤0.01% | 1711 |
|
|
2022
Q2 | $121K | Buy |
15,300
+2,600
| +20% | +$31.4K | ﹤0.01% | 1723 |
|
|
2022
Q1 | $300K | Sell |
12,700
-500
| -4% | -$14.1K | ﹤0.01% | 1604 |
|
|
2021
Q4 | $451K | Hold |
13,200
| – | – | ﹤0.01% | 1513 |
|
|
2021
Q3 | $233K | Buy |
13,200
+4,400
| +50% | +$188K | ﹤0.01% | 1729 |
|
|
2021
Q2 | $394K | Sell |
8,800
-1,200
| -12% | -$39.6K | ﹤0.01% | 1639 |
|
|
2021
Q1 | $259K | Hold |
10,000
| – | – | ﹤0.01% | 1752 |
|
|
2020
Q4 | $201K | Buy |
+10,000
| New | +$215K | ﹤0.01% | 1740 |
|
|
2020
Q3 | – | Sell |
-19,800
| Closed | -$349K | – | 2262 |
|
|
2020
Q2 | $349K | Buy |
19,800
+2,200
| +13% | +$27.6K | ﹤0.01% | 1482 |
|
|
2020
Q1 | $124K | Hold |
17,600
| – | – | ﹤0.01% | 1651 |
|
|
2019
Q4 | $124K | Buy |
+17,600
| New | +$175K | ﹤0.01% | 1747 |
|
|
2018
Q2 | – | Sell |
-13,800
| Closed | -$118K | – | 2165 |
|
|
2018
Q1 | $118K | Buy |
13,800
+11,400
| +475% | +$215K | ﹤0.01% | 1567 |
|
|
2017
Q4 | $49K | Hold |
2,400
| – | – | ﹤0.01% | 1752 |
|
|
2017
Q3 | $42K | Hold |
2,400
| – | – | ﹤0.01% | 1811 |
|
|
2017
Q2 | $27K | Hold |
2,400
| – | – | ﹤0.01% | 1866 |
|
|
2017
Q1 | $30K | Hold |
2,400
| – | – | ﹤0.01% | 1808 |
|
|
2016
Q4 | $52K | Hold |
2,400
| – | – | ﹤0.01% | 1790 |
|
|
2016
Q3 | $50K | Buy |
+2,400
| New | +$32.8K | ﹤0.01% | 1763 |
|
Other funds holding PTGX
FCM
RI
VPM
VCM
JJ
STRS Ohio's PTGX Position: Q1 2026 in Review
STRS Ohio reduced its Protagonist Therapeutics (PTGX) stake by 3.1% in Q1 2026, selling an estimated $44.3K and leaving 15,400 shares worth $1.62M. The position accounts for 0.01% of the portfolio, ranked #609.
STRS Ohio first reported a position in PTGX in Q3 2016 and has held it in 32 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- STRS Ohio held 15,400 shares of Protagonist Therapeutics worth $1.62M as of Q1 2026.
- STRS Ohio sold 500 Protagonist Therapeutics shares in Q1 2026, an estimated $44.3K.
- Protagonist Therapeutics made up 0.01% of STRS Ohio's portfolio in Q1 2026, its #609 holding.
- STRS Ohio first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 32 quarters since.
- 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on STRS Ohio's 13F filing for Q1 2026, filed 24 Apr 2026.